0000000000172506

AUTHOR

Frédéric Bibeau

showing 2 related works from this author

Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.

2021

ABSTRACT Anti-PD1/PD-L1-directed immune checkpoint inhibitors are game changers in advanced non-small-cell lung cancer, but biomarkers are lacking. The aim of our study was to find clinically relevant biomarkers of the efficacy of ICI in non-squamous NSCLC. We conducted a retrospective study of patients receiving ICI for advanced non squamous NSCLC in two cohorts. For a subset of patients, RNAseq data were generated on tumor biopsy taken before ICI. The primary end point was progression-free survival under ICI. Secondary end point was overall survival from ICI initiation. In the cohort, we studied 231 patients. Clinico-pathological characteristics included KRAS mutant status (n = 88), TTF1-…

Oncologymedicine.medical_specialtyLIPI scoreLung Neoplasmsmedicine.medical_treatmentImmunologyThyroid Nuclear Factor 1Adenocarcinoma of Lungmedicine.disease_causeTTF1Internal medicinePD-L1Carcinoma Non-Small-Cell LungmedicineClinical endpointKRASImmunology and AllergyHumansLung cancerImmune Checkpoint InhibitorsRC254-282Retrospective StudiesOriginal Researchbiologybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensprognostic factorsRetrospective cohort studyImmunotherapyRC581-607medicine.diseasePrognosisOncologyCohortbiology.proteinAdenocarcinomaKRASimmunotherapyImmunologic diseases. AllergybusinessAdenocarcinoma lung cancerBiomarkersResearch ArticleOncoimmunology
researchProduct

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastri…

2021

International audience; Gastric or gastro-oesophageal junction (GEJ) adenocarcinomas present poor overall survival (OS). First-line chemotherapy regimen for patients with HER2-negative tumours is based on a doublet or triplet of fluoropyrimidine plus platinum salt ± taxane. Second-line chemotherapy (Docetaxel or Irinotecan) improves OS which nonetheless remains poor (around 5 months). The first results of immune checkpoint inhibitors (anti-PD-1) combined with chemotherapy in metastatic gastric and GEJ cancers were discordant in recent phase III trials. Data on dual-blockade (anti-PD-L1 or anti-PD-1 plus anti-CTLA-4) plus chemotherapy are lacking. DURIGAST is a randomised, multicenter, non-c…

OncologyMalemedicine.medical_specialtyDurvalumabEsophageal NeoplasmsLeucovorinPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerAdenocarcinomaAntibodies Monoclonal Humanized03 medical and health sciencesImmune checkpoint inhibitors0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/CancerStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChemotherapyTaxaneHepatologybusiness.industryGastroenterologyAntibodies Monoclonal[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyChemotherapy regimen[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology3. Good healthIrinotecanTreatment OutcomeDocetaxel030220 oncology & carcinogenesisFOLFIRI030211 gastroenterology & hepatologyCamptothecinFemaleEsophagogastric JunctionFluorouracilFrancebusinessGastric cancerTremelimumabmedicine.drug
researchProduct